SHREEPAC.BO · BSE
SHREE PACETRONIX LTD.
₹186.2
-1.19% (-₹2.25)
Prev. close
₹188.45
Volume
4,371
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About SHREE PACETRONIX LTD.
Shree Pacetronix Limited, through its subsidiary, manufactures and sells implantable cardiac pacemakers in India and internationally. The company offers pacemakers, an anti-bradycardia implantable device for permanent ventricular or atrial pacing applications; and pacing leads that consist of one or more conductors insulated with a sheath of material, such as silicone rubber, polyethylene or polyurethane for use with pulse generators for long term cardiac pacing. It also provides pacing system analyzers, a dual chamber pacing system analyzer used to analyze electrode positioning in the heart of patient while implanting the permanent pacemaker. The company was incorporated in 1988 and is based in Pithampur, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Atul Kumar Sethi
Headquarters
Pithampur
Employees
132
Website
pacetronix.comExchange
View on BSE ↗Key stats
Market cap
₹70.66 Cr
P/E ratio (TTM)
22.0
EPS (TTM)
₹8.57
Beta (1Y · daily vs NIFTY 50)
1.40
Beta (5Y · monthly vs NIFTY 50)
2.03
Shares float
8.87 L
EPS · quarter ended Jun 2026
₹1.94
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹7.56 Cr | ₹9.23 Cr | ₹20.26 Cr | ₹22.04 Cr | ₹16.80 Cr | ₹21.64 Cr | |
| EBITDA | ₹99.50 L | ₹1.85 Cr | ₹5.50 Cr | ₹5.94 Cr | ₹2.43 Cr | ₹5.36 Cr |
| ₹5.30 L | ₹78.10 L | ₹3.26 Cr | ₹3.36 Cr | ₹74.99 L | ₹3.14 Cr | |
| Diluted EPS | ₹0.15 | ₹2.17 | ₹9.06 | ₹9.33 | ₹2.08 | ₹8.47 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹16.54 Cr | ₹21.75 Cr | ₹23.05 Cr | ₹25.71 Cr | |
| — | — | ₹2.19 Cr | ₹4.30 Cr | ₹5.07 Cr | ₹2.68 Cr | |
| Stockholders' equity | — | — | ₹9.67 Cr | ₹13.03 Cr | ₹13.78 Cr | ₹18.11 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1.69 Cr | ₹-3,559.53 | ₹-79,021 | ₹2.92 Cr | |
| Investing cash flow | — | — | ₹-1.41 Cr | ₹-1.67 L | ₹-4.13 L | ₹-77.70 L |
| — | — | ₹-1.10 Cr | ₹1.75 L | ₹18.92 L | ₹-1.61 Cr | |
| Capital expenditure | — | — | ₹-1.23 Cr | ₹-1.38 L | ₹-71.67 L | ₹-1.23 Cr |
| End cash position | — | — | ₹7.13 L | ₹11,420.52 | ₹25.42 L | ₹78.95 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| SHREE PACETRONIX LTD. | ₹69.67 Cr | ₹185.8 | 21.7 | 3.85 | 17.4% | 0.15 | +28.8% | -13.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Shree Pacetronix: FY26 Net Profit Surges 211% to ₹30.17 Crore
Shree Pacetronix Limited reported a 211% surge in net profit to ₹30.17 crore for fiscal year 2026. This significant increase was driven by improved operational performance and effective cost management. The company also saw its net profit margin rise to 13.95% and return on net worth to 17.18%.
Shree Pacetronix consolidated net profit rises 15.15% in the June 2026 quarter
Business Standard · 1 month ago